wassem wrote: Hi Tom I liked your article, you covered all the benefits of the thin client computing. In the article you mentioned the low power benefit, and mentioned the HP computer, as low cost solution, but I think that our product the Cubox that Costs 120$ and needs only 3 Watt of power could be another excellent solution.
PARSIPPANY, N.J., Nov. 5, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the third quarter ended September 30, 2012. Summary of third quarter and subsequent financial and operating highlights include:
Signed multi-year Sales Services contract valued at up to $150 million with Top 5 global pharmaceutical company.
Gerald J. Melillo promoted to President, Sales Services.
Condensed Summary Statement of Continuing Operations
3rd Quarter Ended
Nine Months Ended
September 30,*
September 30,*
2012
2011
2012
2011
Revenue, net
$ 31,781
$ 36,069
$ 91,267
$ 119,008
Gross profit
5,939
7,675
19,875
23,770
Operating expenses:
Compensation expense
4,075
4,171
12,726
15,150
Other SG&A
2,620
3,309
8,442
10,885
Total operating expenses
6,695
7,480
21,168
26,035
Operating (loss) income
$ (756)
$ 195
$ (1,293)
$ (2,265)
Other expense, net
-
(48)
(15)
(122)
Provision (benefit) for income tax
74
183
219
(512)
Loss from continuing operations
$ (830)
$ (36)
$ (1,527)
$ (1,875)
Diluted loss per share from continuing operations
$ (0.06)
$ -
$ (0.10)
$ (0.13)
*Unaudited
CEO Comments Commenting on the company's results, Nancy Lurker, chief executive officer of PDI, Inc., noted, "As expected, third quarter revenue was below that of the same period in 2011 due primarily to the timing and implementation of new contracts. To date, we have won more than $250 million of new contracts and renewals in 2012. Due to the timing of these wins and the execution timelines of these contracts, we expect that only approximately $40 million will impact revenue in 2012. Factoring in this activity, we now estimate that total revenue for the full year of 2012 will be in the range of $127 - $130 million.
"Gross margins on our new Sales Services business in 2012 continue to trend lower than historical rates, including the $150 million win announced recently. We expect the gross margin percentage for the full year of 2012 to remain essentially flat compared to 2011, and to decline in 2013 as new wins with lower margins are executed. From an operating standpoint, we will continue to maintain tight cost controls. For the full year of 2012, excluding the previously announced fourth quarter charges for severance and facilities realignment, we expect a small operating loss and positive adjusted EBITDA in the range of 1% - 2% of revenue.
"We will enter 2013 with a strong backlog of business under contract. Furthermore, we continue to be optimistic that outsourcing will continue to grow and become more the standard in the pharmaceutical industry. I am also pleased to have announced the promotion of Gerry Melillo to the position of president, Sales Services. With this change, Gerry will bring increased focus and leadership, as well as his rich and deep background in the pharmaceutical industry, to our Sales Services segment."
Business Review - Continuing Operations Revenue- For the third quarter of 2012, revenue of $31.8 million was $4.3 million lower than the third quarter of 2011. Revenue in the Product Commercialization segment increased but was more than offset by a decrease in revenue from both Sales Services and Marketing Services.
Sales Services segment revenue for the third quarter of 2012 of $25.0 million was $4.2 million lower than the third quarter of 2011. Due primarily to the timing of signing and start dates of new contract wins, revenue from these wins was not sufficient to offset certain contracts renewing for smaller amounts and the anticipated expiration of certain other contracts.
Marketing Services segment revenue for the third quarter of 2012 of $2.2 million was $1.8 million lower than the third quarter of 2011. This decrease was primarily due to a decrease in Group DCA revenue due to fewer contract signings and delays in our customer's medical legal regulatory approval process.
Product Commercialization Services segment revenue for the third quarter of 2012 was $4.6 million, $1.7 million higher than the third quarter of 2011.
Gross Profit- For the third quarter of 2012, gross profit of $5.9 million was $1.7 million lower than the third quarter of 2011. At the same time, the gross profit percentage decreased to 19% in 2012 from 21% in 2011. The overall decrease in gross profit dollars and percentage was driven primarily by the decreases in both Sales and Marketing Services.
Sales Services segment gross profit for the third quarter of 2012 of $4.2 million was $1.4 million lower than the third quarter of 2011. This decrease was the result of lower revenue. Sales Services gross profit percentage declined in 2012 due primarily to lower margins being realized on new business.
Marketing Services segment gross profit for the third quarter of 2012 of $0.4 million was $1.2 lower when compared to 2011 as a result of lower revenue and a lower gross profit percentage within the segment.
Product Commercialization Services segment gross profit for the third quarter of 2012 of $1.4 million was $0.8 million higher than 2011.
Total Operating Expenses- For the third quarter of 2012, total operating expenses were $6.7 million; $0.8 million lower than the third quarter of 2011. The decrease is a result of the company's continuing focus on cost reduction.
Operating Loss- For the third quarter of 2012 the operating loss from continuing operations was $0.8 million, a decrease of approximately $1.0 million when compared to operating income of $0.2 million in the third quarter of 2011. The decrease is primarily attributable to the decrease in revenue and gross profit when compared to the prior year quarter.
Liquidity and Cash Flow- Adjusted EBITDA for the third quarter of 2012 was $0.2 million compared to $1.3 million in 2011. Cash and cash equivalents as of September 30, 2012 were $60.5 million, up $3.6 million from June 30, 2012 but down $3.8 million from prior year end.
The decrease in cash from year end is primarily attributable to the payments of severance and close-out costs associated with the fourth quarter 2011 sale of our Pharmakon business unit and right-sizing of the Group DCA unit and a 2012 scheduled $1.5 million payment to the sellers of Group DCA.
As of September 30, 2012, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.
Non-GAAP Financial Measures In addition to the United States generally accepted accounting principles, or GAAP, results provided in this document, PDI has provided certain non-GAAP financial measures to help evaluate the results of its performance. The company believes that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.
Adjusted EBITDA is a non-GAAP metric used by management to measure cash flow of the core operating business and liquidity. Adjusted EBITDA is defined as operating income (loss), plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses.
Adjusted EBITDA (Unaudited)
3rd Quarter Ended
Nine Months Ended
September 30,
September 30,
2012
2011
2012
2011
Operating (loss) income
$ (756)
$ 195
$ (1,293)
$ (2,265)
Depreciation and amortization
494
693
1,490
2,066
Stock compensation
484
424
1,520
1,683
Adjusted EBITDA
$ 222
$ 1,312
$ 1,717
$ 1,484
The company also presented Adjusted EBITDA on a forward-looking basis as part of its outlook for the full year 2012. Relative to the full year of 2012, the company estimates depreciation of approximately $2.0 million, non-cash stock compensation of $1.9 million and no other non-cash expenses.
Conference Call As previously announced, PDI will hold a conference call tomorrow, Tuesday, November 6, 2012 to discuss financial and operational results of the third quarter ended September 30, 2012 as follows:
Time: 8:30 AM (ET)
Dial-in numbers: (866) 644-4654 (U.S. and Canada) or (706) 643-1203
The teleconference replay will be available two hours after completion through November 10, 2012 at (800) 585-8367 (U.S. and Canada) or (404) 537-3406. The replay pass code is 34905834. The archived web cast will be available for one year.
About PDI, Inc. PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.
Forward-Looking Statements This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2011, and PDI's subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
(Tables to Follow)
PDI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
($ in thousands, except per share data)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2012
2011
2012
2011
Revenue, net
$ 31,781
$ 36,069
$ 91,267
$ 119,008
Cost of services
25,842
28,394
71,392
95,238
Gross profit
5,939
7,675
19,875
23,770
Compensation expense
4,075
4,171
12,726
15,150
Other selling, general and administrative expenses
2,620
3,309
8,442
10,885
Total operating expenses
6,695
7,480
21,168
26,035
Operating (loss) income
(756)
195
(1,293)
(2,265)
Other expense, net
-
(48)
(15)
(122)
(Loss) income from continuing operations before
income tax
(756)
147
(1,308)
(2,387)
Provision (benefit) for income tax
74
183
219
(512)
Loss from continuing operations
(830)
(36)
(1,527)
(1,875)
(Loss) income from discontinued operations, net of tax
(189)
(166)
(204)
227
Net loss
$ (1,019)
$ (202)
$ (1,731)
$ (1,648)
Basic and diluted (loss) income per share of common stock:
From continuing operations
$ (0.06)
$ -
$ (0.10)
$ (0.13)
From discontinued operations
(0.01)
(0.01)
(0.02)
0.02
Net loss per basic and diluted share of common stock
OpenStack is easily installed using a package called Packstack. Redhat is one of the primary contributors to packstack and my install experience is similar to the installation of RDO, described here
The procedure is quite simple:
Install Redhat, Fedora or Centos on one or more x86 se...
Metacloud plays hardball.
It has no patience with pilots or proofs-of-concept. It’ll only do production Infrastructure-as-a-Service installations, which is kind of uppity for a start-up that only hit the radar last October – even if it did come out of the closet with an unidentified ...
Red Hat made its power play Wednesday. One it’s been itching to make for a couple of years. One that it hopes will ultimately jam a stick through the spokes of VMware’s front wheel. And to make sure that happens it’ll be telling everybody who’ll listen that its widgetry is a third the ...
Cloud computing is the game changer for the life sciences industry, according to an article on PharmaBiz.com.
Globally, pharma majors are deploying cloud technology because it provides data security, compliance and transparency, according to Vikram Anand, associate vice president, clo...
One of the cloud’s biggest draws is the capability to virtualize computing resources, allowing it to be consumed with the click of a mouse. But behind that simple click is an enormous infrastructure challenge that has recently been cited as a major cause for slower enterprise adoption....
In the old world of IT, if you didn't have hardware capacity or the budget to buy more, your project was dead in the water. Budget constraints can leave some of the best, most creative and most ingenious innovations on the cutting room floor. It’s a true dilemma for developers and inno...
About Newsfeeds / Video Feeds
.gif)
OpenStack is easily installed using a package called Packstack. Redhat is one of the primary contributors to packstack and my install experience is similar to the installation of RDO, described here
The procedure is quite simple:
Install Redhat, Fedora or Centos on one or more x86 se...
Metacloud plays hardball.
It has no patience with pilots or proofs-of-concept. It’ll only do production Infrastructure-as-a-Service installations, which is kind of uppity for a start-up that only hit the radar last October – even if it did come out of the closet with an unidentified ...
Red Hat made its power play Wednesday. One it’s been itching to make for a couple of years. One that it hopes will ultimately jam a stick through the spokes of VMware’s front wheel. And to make sure that happens it’ll be telling everybody who’ll listen that its widgetry is a third the ...
Cloud computing is the game changer for the life sciences industry, according to an article on PharmaBiz.com.
Globally, pharma majors are deploying cloud technology because it provides data security, compliance and transparency, according to Vikram Anand, associate vice president, clo...
One of the cloud’s biggest draws is the capability to virtualize computing resources, allowing it to be consumed with the click of a mouse. But behind that simple click is an enormous infrastructure challenge that has recently been cited as a major cause for slower enterprise adoption....
In the old world of IT, if you didn't have hardware capacity or the budget to buy more, your project was dead in the water. Budget constraints can leave some of the best, most creative and most ingenious innovations on the cutting room floor. It’s a true dilemma for developers and inno...
